Haleon (HLN) Depreciation & Amortization (CF) (2022 - 2023)
Haleon (HLN) posted Depreciation & Amortization (CF) of $121.6 million for Q4 2023, up 26.46% on a QoQ basis from $96.2 million in Q4 2022, and up 26.46% year-over-year from $96.2 million in Q4 2022.
Haleon (HLN) Depreciation & Amortization (CF) (2022 - 2023) Analysis & Trends
Haleon's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $121.6 million for Q4 2023.
- Quarterly Depreciation & Amortization (CF) rose 26.46% year-over-year to $121.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $121.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $316.4 million, up 10.02% from the prior year.
- Depreciation & Amortization (CF) was $121.6 million for Q4 2023 at Haleon, up from $96.2 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $121.6 million in Q4 2023 and bottomed at $96.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 121.63 Mn |
| Dec 31, 2023 | 121.63 Mn |
| Dec 31, 2022 | 96.18 Mn |
| Dec 31, 2022 | 96.18 Mn |